A nanopore-based sequencing dataset of mitochondrial DNA of cisplatin-resistant cells derived from oral squamous cell carcinoma cell lines
Mitochondrial DNA (mtDNA) alterations, including copy-number variation, point mutations, and methylation changes, have been reported in various cancers, suggesting their significant role on cancer development, survival and therapeutic resistance. In this work, drug-resistant cells from two human oral squamous cell carcinoma cell lines, namely SAS and H103, were derived by repeated treatments with cisplatin. MtDNA sequencing of the derived drug-resistant cells was performed to examine the potential involvement of mtDNA alterations in the development of cisplatin-resistant oral squamous cell carcinomas. The increased level of resistance against cisplatin was determined by measurements of cell viability after 72 h treatments with cisplatin using CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (MTS assay; Promega Inc., USA). Briefly, the derived cisplatin-resistant SAS and H103 cells had reduced sensitivity towards cisplatin, yielding higher IC50 values of cisplatin compared to their parental cells. The mtDNA was extracted, enriched and processed for both native DNA and amplicon sequencing. Sequencing-ready native DNA and amplicons were analyzed using a MinION sequencer (Oxford Nanopore Technologies, UK). The sequencing data were acquired by the MinKNOW software (Oxford Nanopore Technologies, UK). The data may be analyzed alongside other similar datasets to explore the underlying cisplatin resistance mechanisms in OSCC. The mtDNA sequencing datasets of the parental cells of the derived cisplatin-resistant cells have been deposited previously (SRA Accession No.: PRJNA712949).